Navigation Links
AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
Date:4/15/2009

QUEBEC CITY, April 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it will present two posters on its PI3K inhibitor compound, AEZS-126, as well as a poster on its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, at the American Association for Cancer Research (AACR) Annual Meeting, to be held on April 18-22, 2009 at the Colorado Convention Center in Denver, Colorado.

    AEZS-126 (Poster #3705)

    - Entitled, "AEZS-126, a new orally bioavailable PI3K inhibitor with
      antitumor effects", I. Seipelt, S. Baasner, M. Gerlach, M. Teifel, J.
      Fensterle, L. Blumenstein, G. Mueller and E. Guenther, the poster
      focuses on ADMET and safety profiling of the compound, as well as in
      vivo pharmacokinetic experiments and mouse xenograft antitumor studies.

    AEZS-126 (Poster #3706)

    - Entitled, "In vitro profiling of the potent and selective PI3K
      inhibitor, AEZS-126", I. Seipelt, M. Gerlach, L. Blumenstein, G.
      Mueller, M.Teifel, E. Polymeropoulos and E. Guenther, the poster
      outlines the key in vitro characteristics of this compound that led to
      its selection for in vivo development.

    Both posters will be presented on Tuesday, April 21, 2009, between 8 a.m.
    and 12 p.m. (MT), during the Experimental and Molecular Therapeutics 23
    session in Hall B-F, Poster Section 35.

    AEZS-112 (Poster #5567)

    - Entitled, "Phase I dose-escalation, safety, and pharmacokinetic study
      of weekly oral AEZS-112, a small molecule anticancer agent in patients
      with advanced cancer and lymphoma", D. W. Northfelt, P. Griffin, H.
      Block, H. Sindermann, M. Teifel, D. Von Hoff, D. Mendelson, the poster
      outlines Phase 1 results for this orally-active tubulin and
      topoisomerase II inhibitor compound, in patients with advanced solid
      tumors and lymphoma, which may potentially provide a new therapeutic
      approach for the treatment of cancer.

    The poster will be presented on Wednesday, April 22, 2009, between 8 a.m.
and 12 p.m. (MT) during the Experimental and Molecular Therapeutics 42 session
in Hall B-F, Poster Section 37.

Copies of the abstracts that served for these posters are currently available and can be viewed on-line through the AACR 2009 Meeting website at: http://www.abstractsonline.com/viewer/?mkey=%7BD007B270%2DE8F6%2D492D%2D803B%2D7582CE7A0988%7D

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche ... with peritoneal or pleural mesothelioma. Their findings are the subject of a new article ... Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients ...
(Date:6/23/2016)... -- A person commits a crime, and the detective uses ... criminal down. An outbreak of foodborne illness makes ... uses DNA evidence to track down the bacteria that caused ... not. The FDA has increasingly used a complex, cutting-edge technology ... Put as simply as possible, whole genome sequencing is a ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... June 23, 2016  Blueprint Bio, a company dedicated ... the medical community, has closed its Series A funding ... . "We have received a commitment from ... we need to meet our current goals," stated ... the runway to complete validation on the current projects ...
Breaking Biology Technology:
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
Breaking Biology News(10 mins):